• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺瘤切除术后结直肠癌的粪便免疫化学检测监测:中国一项基于人群的纵向队列关联研究。

Fecal immunochemical test surveillance in colorectal cancer following adenoma resection: A longitudinal, population-based linked cohort study in China.

作者信息

Zhao Jianhui, Liu Chengcheng, Yang Jinhua, Huang Yanqin, Xu Liying, Xiao Qian, Jin Mingjuan, Kong Xiangxing, Hu Yeting, Li Qilong, Zhang Suzhan, Li Xue, Zheng Shu, Chen Kun, Ding Kefeng

机构信息

Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

PLoS Med. 2025 Sep 2;22(9):e1004687. doi: 10.1371/journal.pmed.1004687. eCollection 2025 Sep.

DOI:10.1371/journal.pmed.1004687
PMID:40892900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12416832/
Abstract

BACKGROUND

Although the fecal immunochemical test (FIT) is widely utilized in colorectal cancer (CRC) screening because of its noninvasive, rapid, and cost-effective characteristics, its effectiveness in post-adenoma resection surveillance remains unclear. This study aims to evaluate the benefits of follow-up FIT surveillance in individuals with adenoma resection and to identify risk factors associated with adenoma recurrence.

METHODS AND FINDINGS

As part of China's National Screening Project, we identified a total of 5,911 individuals who underwent adenoma removal during the first round of CRC screening in Jiashan and Haining between 2006 and 2021. All individuals with adenoma removal were invited to participate in a second CRC screening; 2,448 accepted and chose either direct colonoscopy surveillance (n = 989) or FIT surveillance (n = 1,459), while 3,463 declined. The Clone-Censor-Weight method was applied to mitigate time-related biases. Cox proportional hazards and Poisson regression models were used to evaluate the benefits of follow-up surveillance strategies after adenoma resection, adjusting for age, sex, baseline adenoma grade, family history of CRC in first-degree relatives, symptoms, chronic appendicitis or cholecystitis, and stressful life events. Additionally, we examined the risk factors associated with adenoma recurrence using logistic regression. The outcomes were the long-term incidence of CRC and the recurrence of adenomas following adenoma resection. Over average follow-up of 7.79 and 7.46 years, participants who underwent protocol-adherent follow-up FIT surveillance had a 44% lower CRC risk (hazard ratio [HR] = 0.56, 95% confidence interval [CI]: 0.31, 0.98; p = 0.044), and those who underwent direct colonoscopy had a 51% lower risk (HR = 0.49, 95% CI [0.27, 0.89]; p = 0.019), compared to individuals who refused follow-up surveillance. Compared with the direct follow-up colonoscopy group (53.56 per 100,000 person-years), the long-term CRC incidence rates were 70.38 for the follow-up negative FIT group and 80.14 for the positive FIT with adherence to colonoscopy group, with no statistically significant differences (p = 0.852; p = 0.834). Notably, participants who did not undergo colonoscopy following a positive FIT had a significantly increased CRC risk compared to those in the direct follow-up colonoscopy group, with an adjusted incidence rate ratio (aIRR) of 6.64 (95% CI [1.11, 39.83]; p = 0.038). Alcohol consumption (nondrinkers versus >3 times per week: adjusted odds ratio [aOR] = 0.43, 95% CI [0.27, 0.69]; p < 0.001) was associated with adenoma recurrence. Moreover, smoking (current smokers versus nonsmokers: aOR = 3.72, 95% CI [1.19, 11.60]; p = 0.024), obesity (obese versus normal: aOR = 3.21, 95% CI [1.17, 8.80]; p = 0.023), and having advanced adenomas at baseline (aOR = 3.30, 95% CI [1.41, 7.69]; p = 0.006) were associated with recurrence of advanced adenomas. Given the limited number of incident CRC cases and the observational study design, conclusions regarding the impact of follow-up FIT surveillance after adenoma removal should be interpreted with caution.

CONCLUSION

Protocol-adherent follow-up FIT surveillance after adenoma removal was associated with reduced long-term CRC risk, comparable to that observed with direct colonoscopy. However, improving adherence to colonoscopy after a positive FIT surveillance is crucial.

摘要

背景

尽管粪便免疫化学检测(FIT)因其无创、快速且经济高效的特点而被广泛应用于结直肠癌(CRC)筛查,但其在腺瘤切除术后监测中的有效性仍不明确。本研究旨在评估腺瘤切除术后进行FIT随访监测的益处,并确定与腺瘤复发相关的危险因素。

方法与结果

作为中国国家筛查项目的一部分,我们共识别出5911名在2006年至2021年期间于嘉善和海宁进行的第一轮CRC筛查中接受腺瘤切除的个体。所有接受腺瘤切除的个体均被邀请参加第二轮CRC筛查;2448人接受邀请并选择直接结肠镜监测(n = 989)或FIT监测(n = 1459),而3463人拒绝。采用克隆-审查-加权方法来减轻时间相关偏倚。使用Cox比例风险模型和泊松回归模型评估腺瘤切除术后随访监测策略的益处,并对年龄、性别、基线腺瘤分级、一级亲属的CRC家族史、症状、慢性阑尾炎或胆囊炎以及应激性生活事件进行校正。此外,我们使用逻辑回归分析与腺瘤复发相关的危险因素。结局指标为CRC的长期发病率以及腺瘤切除术后腺瘤的复发情况。在平均7.79年和7.46年的随访中,接受依从方案的FIT随访监测的参与者患CRC的风险降低了44%(风险比[HR] = 0.56,95%置信区间[CI]:0.31,0.98;p = 0.044),接受直接结肠镜检查的参与者风险降低了51%(HR = 0.49,95% CI [0.27,0.89];p = 0.019),相比拒绝随访监测的个体。与直接随访结肠镜检查组(每100,000人年53.56例)相比,FIT随访阴性组的长期CRC发病率为70.38例,FIT阳性且依从结肠镜检查组为80.14例,差异无统计学意义(p = 0.852;p = 0.834)。值得注意的是,FIT阳性后未接受结肠镜检查的参与者患CRC的风险相比直接随访结肠镜检查组显著增加,校正发病率比(aIRR)为6.64(95% CI [1.11,[39.83];p = 0.038)。饮酒(不饮酒者与每周>3次饮酒者:校正优势比[aOR] = 0.43,95% CI [0.27,0.69];p < 0.001)与腺瘤复发相关。此外,吸烟(当前吸烟者与非吸烟者:aOR = 3.72,95% CI [1.19,11.60];p = 0.024)、肥胖(肥胖者与正常者:aOR = 3.21,95% CI [1.17,8.80];p = 0.023)以及基线时患有高级别腺瘤(aOR = 3.30,95% CI [1.41,7.69];p = 0.006)与高级别腺瘤复发相关。鉴于新发CRC病例数量有限且为观察性研究设计,关于腺瘤切除术后FIT随访监测影响的结论应谨慎解读。

结论

腺瘤切除术后依从方案的FIT随访监测与降低长期CRC风险相关,与直接结肠镜检查的效果相当。然而,提高FIT阳性后结肠镜检查的依从性至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/b66453b7abdf/pmed.1004687.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/6858d8f04013/pmed.1004687.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/b82e9ffea71a/pmed.1004687.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/f4d241f84b15/pmed.1004687.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/b66453b7abdf/pmed.1004687.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/6858d8f04013/pmed.1004687.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/b82e9ffea71a/pmed.1004687.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/f4d241f84b15/pmed.1004687.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aff/12416832/b66453b7abdf/pmed.1004687.g004.jpg

相似文献

1
Fecal immunochemical test surveillance in colorectal cancer following adenoma resection: A longitudinal, population-based linked cohort study in China.腺瘤切除术后结直肠癌的粪便免疫化学检测监测:中国一项基于人群的纵向队列关联研究。
PLoS Med. 2025 Sep 2;22(9):e1004687. doi: 10.1371/journal.pmed.1004687. eCollection 2025 Sep.
2
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
3
Chemoprevention of colorectal cancer: systematic review and economic evaluation.结直肠癌的化学预防:系统评价和经济评估。
Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320.
4
Interval Colorectal Cancers in a Fecal Immunochemical Test-Based Screening Program.基于粪便免疫化学检测的筛查项目中的间隔期结直肠癌
JAMA Netw Open. 2025 Jul 1;8(7):e2523441. doi: 10.1001/jamanetworkopen.2025.23441.
5
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.多靶点粪便免疫化学试验与粪便免疫化学试验用于结直肠癌筛查项目:一项具有配对设计的横断面干预研究。
BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2.
6
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas.膳食纤维用于预防复发性结直肠腺瘤和癌。
Cochrane Database Syst Rev. 2017 Jan 8;1(1):CD003430. doi: 10.1002/14651858.CD003430.pub2.
7
Risk of advanced neoplasia after removal of colorectal adenomas with high-grade dysplasia.高级别异型增生的结直肠腺瘤切除后发生进展性肿瘤的风险。
Surg Endosc. 2024 Jul;38(7):3783-3798. doi: 10.1007/s00464-024-10898-5. Epub 2024 May 28.
8
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.粪便免疫化学检测用于在初级保健中对有下腹部症状的患者进行分流,以确定是否需要转诊疑似结直肠癌患者:一项系统评价和成本效益分析。
Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330.
9
Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program.首次粪便免疫化学试验(FIT)结果为阴性或低风险腺瘤患者第二次FIT筛查的结果:一项全国性FIT筛查项目的结果
Int J Cancer. 2025 Aug 15;157(4):698-708. doi: 10.1002/ijc.35419. Epub 2025 Mar 28.
10
Screening Uptake and Diagnostic Yield of One-time Fecal Immunochemical Testing Vs One-time Colonoscopy for Colorectal Cancer: a Systematic Review and Meta-analysis.一次性粪便免疫化学检测与一次性结肠镜检查对结直肠癌的筛查接受度及诊断率:一项系统评价与Meta分析
J Gastrointest Cancer. 2025 Aug 1;56(1):166. doi: 10.1007/s12029-025-01286-w.

本文引用的文献

1
Decoding the genetic and environmental forces in propelling the surge of early-onset colorectal cancer.解析推动早发性结直肠癌激增的遗传和环境因素。
Chin Med J (Engl). 2025 May 20;138(10):1163-1174. doi: 10.1097/CM9.0000000000003601. Epub 2025 Apr 18.
2
Accuracy and long-term effectiveness of established screening modalities and strategies in colorectal cancer screening: An umbrella review.既定筛查方式和策略在结直肠癌筛查中的准确性和长期有效性:一项伞状综述。
Int J Cancer. 2025 Jul 1;157(1):126-138. doi: 10.1002/ijc.35381. Epub 2025 Feb 25.
3
Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019.
1990年至2019年早发性癌症的发病率、死亡率、疾病负担及风险因素的全球趋势。
BMJ Oncol. 2023 Sep 5;2(1):e000049. doi: 10.1136/bmjonc-2023-000049. eCollection 2023.
4
De-Mystifying the Clone-Censor-Weight Method for Causal Research Using Observational Data: A Primer for Cancer Researchers.揭开使用观察性数据进行因果研究的克隆-审查-权重方法的神秘面纱:癌症研究人员入门指南
Cancer Med. 2024 Dec;13(23):e70461. doi: 10.1002/cam4.70461.
5
Association of clinical characteristics and recurrence of conventional colorectal adenomas with patient age: a single-center study.常规结直肠腺瘤的临床特征及复发与患者年龄的相关性:一项单中心研究
Surg Endosc. 2023 Nov;37(11):8373-8383. doi: 10.1007/s00464-023-10352-y. Epub 2023 Sep 13.
6
Nonadherence to Referral Colonoscopy After Positive Fecal Immunochemical Test Results Increases the Risk of Distal Colorectal Cancer Mortality.粪便免疫化学检测结果呈阳性后未坚持接受转诊结肠镜检查会增加远端结直肠癌死亡风险。
Gastroenterology. 2023 Dec;165(6):1558-1560.e4. doi: 10.1053/j.gastro.2023.08.013. Epub 2023 Aug 19.
7
Target Trial Emulation: A Framework for Causal Inference From Observational Data.目标试验模拟:一种从观察性数据进行因果推断的框架。
JAMA. 2022 Dec 27;328(24):2446-2447. doi: 10.1001/jama.2022.21383.
8
Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.腺瘤切除术后结肠镜随访以降低结直肠癌风险:一项回顾性队列研究。
Health Technol Assess. 2022 May;26(26):1-156. doi: 10.3310/OLUE3796.
9
Current and future colorectal cancer screening strategies.当前和未来的结直肠癌筛查策略。
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531. doi: 10.1038/s41575-022-00612-y. Epub 2022 May 3.
10
Faecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker.腺瘤息肉切除术前和术后粪便血红蛋白浓度接近理想的肿瘤标志物。
Ann Clin Biochem. 2022 Jul;59(4):272-276. doi: 10.1177/00045632221080897. Epub 2022 Mar 2.